Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Discovery To Aid In Diagnosis And Treatment Of Kidney Disease
Researchers from Boston University School of Medicine (BUSM) in collaboration with scientists at the University of Louisville and the University of Nice Sophia Antipolis in France, have identified the target antigen PLA2R in patients with idiopathic membranous nephropathy (kidney disease), which has implications for the diagnosis and treatment of this disease. These findings appear in the July 2 issue of the New England Journal of Medicine.

As Obama Wades Into Health Debate, Tough Choices Await
"As the legislative debate over health care intensifies on Capitol Hill, there is growing clamor for President Obama to step in," the Washington Post reports. The administration has so far left the crafting of legislation in the hands of Congress, but a series of tough choices await the President, who at some point must define "what he"ll accept and what he won"t" in a final bill. His job is made more difficult by recent cost estimates. "A preliminary estimate of the Senate Finance Committee"s draft bill put the price tag of universal coverage at $1.6 trillion over 10 years. That was considerably more than anyone anticipated and forced the committee to delay work on the bill. The cost of the incomplete plan drafted by the Senate Health, Education, Labor and Pensions Committee was pegged at about $1 trillion over 10 years, but the CBO said that would still leave 30 million (rather than the current 46 million) people without coverage."
News of the day
New National Cancer Standards For Sarcoma Services Published, Wales
New standards to improve access to diagnosis and treatment of sarcomas have been published by the Welsh Assembly Government.
Health Insurance

Targacept Announces Decision By AstraZeneca To Advance AZD3480 Program In ADHD

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced that AstraZeneca has informed Targacept that it plans to conduct further development of AZD3480 (TC-1734) for attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million milestone payment to Targacept. AstraZeneca also confirmed plans to continue development of AZD1446 (TC-6683) for Alzheimer"s disease. AZD1446, which is currently in Phase 1, was discovered in the parties" ongoing research collaboration. For Alzheimer"s disease, development of AZD1446 has been prioritized by AstraZeneca over further development of AZD3480. AZD3480 and AZD1446 are selective alpha4beta2 NNR agonists. "We continue to be enthusiastic about neuronal nicotinic receptors as a promising new mechanism in the treatment of multiple cognitive disorders," said Bob Holland, Vice President and Head of the Neuroscience Therapy Area, AstraZeneca. "We believe the therapeutic profile of AZD3480, a non-stimulant, may be an important advance for treating patients with ADHD and we also remain positive about the potential of NNR agonists to treat Alzheimer"s disease." AstraZeneca has presented Targacept with preliminary plans for a robust development program for AZD3480 in ADHD, including clinical studies to include both younger subjects and adults. Under the terms of an amendment to the parties" collaboration agreement, AstraZeneca has agreed to make the $10 million milestone payment described above and Targacept is eligible to receive a lower aggregate milestone stream for AZD3480 if ADHD is the only target indication for which AZD3480 is developed further. Targacept remains eligible to receive over $100 million if development, regulatory and first commercial sale milestones are achieved for AZD3480 only in ADHD, as well as stepped double-digit royalties on any future sales of AZD3480 in any indication. Targacept also continues to be eligible to receive future payments upon the achievement of milestone events for AZD1446 and royalties on any future sales of AZD1446. "We appreciate the efforts and dedication of our colleagues at AstraZeneca as we work together to develop and deliver the promise of NNR Therapeutics to patients affected by cognitive disorders like ADHD and Alzheimer"s disease," said J. Donald deBethizy, Ph.D., President and Chief Executive Officer of Targacept. "In addition to AZD3480 and AZD1446, we remain enthusiastic about the breadth and pharmacological diversity of our portfolio. With our pipeline, strong alliances and a cash runway that we expect to fund our operations for at least the next two years, we are well positioned to execute our business plan." About ADHD Attention deficit/hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders. The principal characteristics of ADHD are inattention, hyperactivity and impulsivity. ADHD is a chronic disorder that develops during childhood, often persists into adulthood and can negatively impair many aspects of daily life, including home, school, work and interpersonal relationships. The market research firm Business Insights estimated that there were approximately 25 million adults and 12.7 million children with ADHD in 2008 in the world"s seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). About Alzheimer"s Disease Alzheimer"s disease is a progressive, degenerative disorder that attacks the brain"s nerve cells, or neurons, resulting in loss of memory, thinking and language skills, and behavioral changes. A 2007 study conducted by researchers at Johns Hopkins University estimated that over 26 million people worldwide suffer from Alzheimer"s disease. The Alzheimer"s Association has estimated that Alzheimer"s disease affects more than five million people in the United States and has projected the number of afflicted Americans age 65 and over to increase by more than 50 percent to 7.7 million by 2030. Current treatment options have limited efficacy and significant side effects in many patients. Targacept


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009